8-K: Pulse Biosciences Appoints New Co-Chairman, Announces Business Updates and Preliminary Q2 2024 Results

Pulse Biosciences appoints Paul LaViolette as Co-Chairman, reports progress in clinical trials, and announces preliminary Q2 2024 financial results.

Summary

• Pulse Biosciences announced the appointment of Paul LaViolette as Co-Chairman of the Board, alongside Robert W. Duggan.
• The company completed the first soft tissue ablation procedures in the U.S. using the Percutaneous Electrode System after FDA clearance.
• They also completed the first epicardial ablation procedures for atrial fibrillation in Europe as part of a feasibility study.
• The endocardial catheter ablation study was expanded to enroll up to 60 patients, with initial ablations commenced in the additional cohort.
• Pulse Biosciences expects to commence pivotal clinical trials for both the Percutaneous Electrode System and the Cardiac Surgical System in 2025.
• The company strengthened its balance sheet with a $60 million gross proceeds rights offering, with potential for an additional $66 million upon warrant exercise.
• Total GAAP costs and expenses for Q2 2024 were $11.7 million, while non-GAAP costs and expenses were $9.4 million.
• Cash and cash equivalents totaled $26.2 million as of June 30, 2024, not including the $60 million from the rights offering.
• Cash used in the second quarter of 2024 was $8.7 million.
• The company granted options to purchase 215,000 shares to ten new employees as an inducement.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant progress in clinical trials, a successful capital raise, and the appointment of a highly experienced board member. The company is making good progress towards commercialization.

Positives

• The appointment of Paul LaViolette brings significant medical technology expertise to the board.
• Successful completion of initial procedures for soft tissue ablation in the U.S. and epicardial ablation in Europe demonstrates progress in clinical trials.
• The oversubscribed rights offering significantly strengthens the company's financial position.
• The expansion of the endocardial catheter ablation study indicates confidence in the technology.
• The company received FDA Breakthrough Device Designation and won FDA Total Product Life Cycle (TPLC) Advisory Program (TAP) designation for the Cardiac Surgery System.

Negatives

• The company reported a cash usage of $8.7 million in the second quarter of 2024.
• The company's total GAAP costs and expenses were $11.7 million for the quarter.

Risks

• The company's future success depends on the successful completion of clinical trials and regulatory approvals.
• The company's ability to commercialize its technology is subject to market acceptance and competition.
• The company's financial performance is subject to fluctuations in research and development expenses.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to commence pivotal clinical trials for the Percutaneous Electrode System and the Cardiac Surgical System in 2025 and a U.S. IDE pivotal clinical study for the endocardial catheter sometime in 2025. The company also plans to continue its clinical work internationally and in the U.S. as it pursues regulatory pathways.

Management Comments

• Burke T. Barrett, President and Chief Executive Officer, stated that the second quarter was very productive with key milestones achieved since the end of the first quarter.
• Robert W. Duggan, Co-Chairman of the Board, expressed excitement about Paul LaViolette joining the board and the expertise he brings.
• Paul LaViolette stated he is honored to join the Board and is excited to help the team build transformational treatments for unmet patient needs.

Industry Context

The company's focus on nano-PFA technology for cardiac ablation and soft tissue treatment aligns with the growing trend of minimally invasive procedures in the medical device industry. The appointment of a seasoned executive like Paul LaViolette also signals a move towards scaling and commercialization.

Comparison to Industry Standards

• Pulse Biosciences is competing with companies like Medtronic, Johnson & Johnson, and Abbott in the cardiac ablation market, all of which have established technologies and market presence.
• The company's nano-PFA technology is a novel approach compared to traditional radiofrequency ablation, potentially offering advantages in terms of tissue selectivity and reduced thermal damage.
• The successful completion of initial procedures and the receipt of FDA designations are positive indicators, but the company still needs to demonstrate efficacy and safety in larger clinical trials.
• The $60 million capital raise is significant for a company of this size, but it will need to continue to raise capital to fund its clinical trials and commercialization efforts.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders benefit from the strengthened balance sheet and the potential for future growth.
• Employees benefit from the company's progress and the grant of inducement options.
• Patients may benefit from the development of new treatment options for atrial fibrillation and soft tissue conditions.
• The company's suppliers and partners may benefit from increased business activity.

Next Steps

• The company expects to commence pivotal clinical trials for the Percutaneous Electrode System and the Cardiac Surgical System in 2025.
• The company expects to commence a U.S. IDE pivotal clinical study for the endocardial catheter sometime in 2025.
• The company will continue to pursue regulatory pathways and generate high-quality clinical data.

Key Dates

Keywords

Nanosecond Pulsed Field Ablation, nano-PFA, Atrial Fibrillation, Soft Tissue Ablation, Cardiac Ablation, Clinical Trials, Medical Technology, FDA Approval, Rights Offering, Board of Directors